Effect of Peroxisome Proliferator-Activated Receptor Agonists on Serum Inflammatory Markers in Diabetic Rats
Background: Inflammation had a key role in several pathological conditions including atherosclerosis. Previous studies indicated that the proxisome proliferator-activated receptors (PPAR) are involved in numerous physiological and pathological conditions. The aim of this study was to investigate the...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | fas |
Published: |
Isfahan University of Medical Sciences
2014-05-01
|
Series: | مجله دانشکده پزشکی اصفهان |
Subjects: | |
Online Access: | http://jims.mui.ac.ir/index.php/jims/article/view/3250 |
Summary: | Background: Inflammation had a key role in several pathological conditions including atherosclerosis. Previous studies indicated that the proxisome proliferator-activated receptors (PPAR) are involved in numerous physiological and pathological conditions. The aim of this study was to investigate the effect of PPAR agonists including PPARα (fenofibrate), PPARβ/δ (GW0742), PPARγ (rosiglitazone) and pan PPAR (bezafibrate) administration on serum high-sensitive C-reactive protein (hsCRP) and interleukine-6 (IL-6) in male diabetic rats.
Methods: The male Wistar rats were received streptozotocin for induction of type I diabetes. Then, they were randomly divided into five groups: diabetic, diabetic + fenofibrate (100 mg/kg/day; gavage), diabetic + GW0742 (1 mg/kg/day, subcutaneous), diabetic + rosiglitazone (8 mg/kg/day; gavage) and diabetic + bezafibrate (400mg/kg/day; gavage). After 21 days, the serum levels of hsCRP and IL-6 were measured using the enzyme-linked immunosorbent assay (ELISA) kits.
Findings: Administration of different PPAR agonists did not alter serum hsCRP and IL-6 concentrations in diabetic animals.
Conclusion: It seems that changes of serum inflammatory markers are not responsible for effects of PPARs agonist in atherosclerosis process and other mechanisms should be studied. |
---|---|
ISSN: | 1027-7595 1735-854X |